HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.
about
Molecular Imaging of Biomarkers in Breast CancerReceptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesA critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsPKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II.Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic miceClinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancerEmerging therapeutic targets in metastatic progression: A focus on breast cancer.Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccinePathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylationEfficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.Patient pathway for breast cancer: turning points and future aspirations.MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study.Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?Taspase1: a 'misunderstood' protease with translational cancer relevance.BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line ModelOvercoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Trastuzumab in the Treatment of Breast Cancer.Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.A new look at the ALK gene in cancer: copy number gain and amplification.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Induction of apoptosis in human cancer cells by targeting mitochondria with gold nanoparticles.The role of ADAM17 in tumorigenesis and progression of breast cancer.Docosahexaenoic Acid-mediated Inhibition of Heat Shock Protein 90-p23 Chaperone Complex and Downstream Client Proteins in Lung and Breast Cancer.The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress.The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells.Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.ADAM10 and ADAM17: New players in trastuzumab tesistance.Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.Fabrication of Calcium Phosphate-Based Nanocomposites Incorporating DNA Origami, Gold Nanorods, and Anticancer Drugs for Biomedical Applications.A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants.
P2860
Q26772870-09092BC1-3BE4-4E5F-8C53-CCA5DFA4E8E7Q27853122-DECC3DF9-C85C-47D7-975C-414BD7BE57F3Q33648150-995A1A88-9390-4572-83D2-2375C75D8FE6Q33709284-FBAF7B25-989E-4663-89FD-746AED376B26Q33712476-8707F989-04CE-4F6E-BD2E-51862EEDA093Q33822560-BB9553BE-AFA7-4668-9003-F95918E25A32Q35682599-6D433AAA-D7F4-44B6-B877-8318E533B837Q36273796-468FCB86-519D-4AC5-9C31-CA8076015713Q36437097-66B4D94F-410C-429A-92C0-EF5F4BCAD531Q36441535-C3280940-EB46-4600-AEA9-A54057BC73F8Q36545638-916FE94B-6637-46ED-800B-7A3CE17984BEQ36653094-8CD1D80D-8E7F-4646-B5B5-956750DC2691Q36854062-D85658D2-727B-42AD-9070-72F0C9D14842Q37289389-F2091D08-2AF6-4B82-A507-F260A8615F6FQ37745916-C78A85F4-AA30-4638-BB7D-7570D4EAECDFQ37748071-6AD0694C-5C31-41FF-ACD6-7113913F10F3Q38310258-659B6F1A-E8CD-4ECA-B859-1C0B93B581CDQ38389148-29959F19-DE20-4891-BAAB-3D41A626A7D6Q38409734-6FEA793C-65FA-452E-AB6D-5BB0FC6AE38AQ38575259-8D59D6E4-879E-4519-9B5A-177F7358249EQ38666356-419C182A-7D9C-452E-B7B8-388FEE131536Q38694128-CA83F3DD-B4DF-4422-94B2-4AAC00B04D6DQ38707896-8E59F994-CE27-4353-BB22-9BEBBF168A31Q38739914-B1053816-E070-43EB-A9A3-4BEEDCA0D39DQ38760664-BE7492C2-B504-4271-95A1-FA177E2A255FQ38760747-B4B5D746-A185-4927-999A-03C980D4F6D6Q38824661-B1FED7E2-CAFF-4C18-8966-B5F9BFC17D24Q38852051-7FAD717E-8C32-4F02-8E3D-AD67B8381363Q38869814-99541803-9E5C-4B86-86C4-FD6A5C2A9882Q38961857-5557614F-335A-4053-A9D8-6BF62D55A6D4Q39158772-21032B9B-20FE-48C3-8EBC-1EA72FAE94C4Q39346175-9EBA26A8-3E4F-4B7B-8CA6-42073026FBAAQ41098254-10635A2E-F6A1-492E-ACF2-0C39C27F833AQ41846641-674BCB8B-47E2-4A46-9E68-8063D1443468Q43106106-D3C2CD32-C9EF-4FDB-9A2D-44E677262188Q47573583-62A81CFB-0052-4B7C-8D77-6D34D2D02686Q47638243-8118E8F0-9C18-4384-9263-07B3986B449CQ47642707-4748E5D8-7D6C-43AD-9DE3-035DC8511E48Q48250617-1E9525F1-3B99-4E97-8DC9-9971127614FBQ48292951-C425408D-E06B-4D4B-9438-BF6B04E729E3
P2860
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HER2-positive advanced breast ...... tunities for drug development.
@ast
HER2-positive advanced breast ...... tunities for drug development.
@en
HER2-positive advanced breast ...... tunities for drug development.
@nl
type
label
HER2-positive advanced breast ...... tunities for drug development.
@ast
HER2-positive advanced breast ...... tunities for drug development.
@en
HER2-positive advanced breast ...... tunities for drug development.
@nl
prefLabel
HER2-positive advanced breast ...... tunities for drug development.
@ast
HER2-positive advanced breast ...... tunities for drug development.
@en
HER2-positive advanced breast ...... tunities for drug development.
@nl
P2860
P921
P356
P1476
HER2-positive advanced breast ...... tunities for drug development.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.388
P407
P5008
P577
2014-07-15T00:00:00Z
2014-11-11T00:00:00Z
P5875
P6179
1006995233